These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 27489794)

  • 1. Proctitis 1 Week after Stereotactic Body Radiation Therapy for Prostate Cancer: Implications for Clinical Trial Design.
    Paydar I; Cyr RA; Yung TM; Lei S; Collins BT; Chen LN; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():167. PubMed ID: 27489794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proctitis following stereotactic body radiation therapy for prostate cancer.
    Joh DY; Chen LN; Porter G; Bhagat A; Sood S; Kim JS; Moures R; Yung T; Lei S; Collins BT; Ju AW; Suy S; Carroll J; Lynch JH; Dritschilo A; Collins SP
    Radiat Oncol; 2014 Dec; 9():277. PubMed ID: 25497602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation Therapy for Prostate Cancer: What is the Appropriate Patient-Reported Outcome for Clinical Trial Design?
    Woo JA; Chen LN; Wang H; Cyr RA; Bhattasali O; Kim JS; Moures R; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2015; 5():77. PubMed ID: 25874188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
    Repka MC; Guleria S; Cyr RA; Yung TM; Koneru H; Chen LN; Lei S; Collins BT; Krishnan P; Suy S; Dritschilo A; Lynch J; Collins SP
    Front Oncol; 2016; 6():122. PubMed ID: 27242962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics and management of late urinary symptom flare following stereotactic body radiation therapy for prostate cancer.
    Woo JA; Chen LN; Bhagat A; Oermann EK; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kumar D; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():122. PubMed ID: 24904833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
    Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
    Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer.
    Pepin A; Pernia M; Danner MT; Ayoob M; Yung TM; Lei S; Collins BT; Simeng S; Aghdam N; Collins SP
    Cureus; 2021 Mar; 13(3):e13780. PubMed ID: 33842156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.
    Sood S; Ju AW; Wang H; Lei S; Uhm S; Zhang G; Suy S; Carroll J; Lynch J; Dritschilo A; Collins SP
    Radiat Oncol; 2013 Aug; 8():197. PubMed ID: 23937800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP).
    Pepin A; Aghdam N; Shah S; Kataria S; Tsou H; Datta S; Danner M; Ayoob M; Yung T; Lei S; Gurka M; Collins BT; Krishnan P; Suy S; Hankins R; Lynch JH; Collins SP
    Front Oncol; 2020; 10():555. PubMed ID: 32432033
    [No Abstract]   [Full Text] [Related]  

  • 10. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15).
    Aghdam N; Pepin A; Buchberger D; Hirshberg J; Lei S; Ayoob M; Danner M; Yung T; Kumar D; Collins BT; Lynch J; Kataria S; Suy S; Collins SP
    Front Oncol; 2020; 10():1060. PubMed ID: 32719744
    [No Abstract]   [Full Text] [Related]  

  • 11. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
    Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
    Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.
    Mercado C; Kress MA; Cyr RA; Chen LN; Yung TM; Bullock EG; Lei S; Collins BT; Satinsky AN; Harter KW; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2016; 6():114. PubMed ID: 27200300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved irritative voiding symptoms 3 years after stereotactic body radiation therapy for prostate cancer.
    Rana Z; Cyr RA; Chen LN; Kim BS; Moures RA; Yung TM; Lei S; Collins BT; Suy S; Dritschilo A; Lynch JH; Collins SP
    Front Oncol; 2014; 4():290. PubMed ID: 25374844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosimetric predictors of acute bowel toxicity after Stereotactic Body Radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
    Repka MC; Carrasquilla M; Paydar I; Wu B; Lei S; Suy S; Collins SP; Kole TP
    Acta Oncol; 2023 Feb; 62(2):174-179. PubMed ID: 36826994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bothersome Hot Flashes Following Neoadjuvant Androgen Deprivation Therapy and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
    Shah S; Pepin A; Jatar S; Hsueh J; Gallagher L; Danner MT; Zwart A; Ayoob M; Yung TM; Kumar D; Aghdam N; Leger PD; Dawson NA; Simeng S; Collins SP
    Cureus; 2024 Mar; 16(3):e55729. PubMed ID: 38586683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Patient-Reported Outcomes to Guide Symptom Management during Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer.
    Danner M; Hung MY; Yung TM; Ayoob M; Lei S; Collins BT; Suy S; Collins SP
    Front Oncol; 2017; 7():227. PubMed ID: 29085804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First Australian experience of treating localised prostate cancer patients with CyberKnife stereotactic radiotherapy: early PSA response, acute toxicity and quality of life.
    Dixit A; Tang C; Bydder S; Kedda MA; Vosikova E; Bharat C; Gill S
    J Med Radiat Sci; 2017 Sep; 64(3):180-187. PubMed ID: 28271639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.
    Paydar I; Pepin A; Cyr RA; King J; Yung TM; Bullock EG; Lei S; Satinsky A; Harter KW; Suy S; Dritschilo A; Lynch JH; Kole TP; Collins SP
    Front Oncol; 2017; 7():5. PubMed ID: 28224113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of Life and Toxicity after SBRT for Organ-Confined Prostate Cancer, a 7-Year Study.
    Katz AJ; Kang J
    Front Oncol; 2014; 4():301. PubMed ID: 25389521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy.
    Pepin A; Shah S; Pernia M; Lei S; Ayoob M; Danner M; Yung T; Collins BT; Suy S; Aghdam N; Collins SP
    Front Oncol; 2021; 11():722852. PubMed ID: 34604059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.